JP2020502218A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502218A5
JP2020502218A5 JP2019533573A JP2019533573A JP2020502218A5 JP 2020502218 A5 JP2020502218 A5 JP 2020502218A5 JP 2019533573 A JP2019533573 A JP 2019533573A JP 2019533573 A JP2019533573 A JP 2019533573A JP 2020502218 A5 JP2020502218 A5 JP 2020502218A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2017/053849 external-priority patent/WO2018115879A1/en
Publication of JP2020502218A publication Critical patent/JP2020502218A/ja
Publication of JP2020502218A5 publication Critical patent/JP2020502218A5/ja
Pending legal-status Critical Current

Links

JP2019533573A 2016-12-21 2017-12-21 骨形成不全症の処置における抗スクレロスチン抗体の使用 Pending JP2020502218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437358P 2016-12-21 2016-12-21
US62/437,358 2016-12-21
PCT/GB2017/053849 WO2018115879A1 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Publications (2)

Publication Number Publication Date
JP2020502218A JP2020502218A (ja) 2020-01-23
JP2020502218A5 true JP2020502218A5 (enExample) 2021-02-04

Family

ID=60888539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533573A Pending JP2020502218A (ja) 2016-12-21 2017-12-21 骨形成不全症の処置における抗スクレロスチン抗体の使用

Country Status (3)

Country Link
US (3) US10961305B2 (enExample)
JP (1) JP2020502218A (enExample)
WO (1) WO2018115879A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7050335B2 (ja) * 2016-12-21 2022-04-08 メレオ バイオファーマ 3 リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
WO2023056355A2 (en) * 2021-09-30 2023-04-06 Mereo Biopharma 3 Limited Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
WO2025036493A1 (en) * 2023-08-17 2025-02-20 Sinomab Bioscience Limited Antibodies targeting rankl and sclerostin and uses thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
SE8804164A0 (sv) 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5229495A (en) 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ZA936478B (en) 1992-09-03 1994-09-30 Regeneron Pharma Dorsal tissue affecting factor and compositions
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
AU2404695A (en) 1994-05-04 1995-11-29 Mount Sinai Hospital Corporation Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
NZ500577A (en) 1997-04-29 2001-02-23 Regeneron Pharma Human cerberus protein that regulates cell function, induce neural development or antagonise bone morphogenic proteins
EP0991759A1 (en) 1997-06-06 2000-04-12 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
US5935852A (en) 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
WO1999061044A1 (en) 1998-05-28 1999-12-02 The Board Of Trustees Of The University Of Arkansas Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DK2261335T3 (en) 1998-11-27 2017-09-18 Ucb Pharma Sa Compositions and Methods for Increasing Bone Mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU3511100A (en) 1999-03-12 2000-10-04 Regeneron Pharmaceuticals, Inc. Novel nucleic acids and polypeptides
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
AU2914501A (en) 1999-12-28 2001-07-09 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
US20020168638A1 (en) 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2001229508A1 (en) 2000-01-31 2001-08-07 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
US20040087016A1 (en) 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
EP1318833A2 (en) 2000-05-12 2003-06-18 The University of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
CA2410912A1 (en) 2000-06-01 2001-12-06 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
JP2004520005A (ja) 2000-06-19 2004-07-08 エフ.ホフマン−ラ ロシュ アーゲー オステオレビン遺伝子多型性
AU2002236558A1 (en) 2000-12-01 2002-06-11 Regents Of The University Of California Method and composition for modulating bone growth
AU2002243495A1 (en) 2001-01-12 2002-07-24 University Of Medicine And Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
CA2465499A1 (en) 2001-11-08 2003-05-15 Merck & Co., Inc. Compositions and methods for treating osteoporosis
AU2002366951A1 (en) 2001-12-10 2003-07-09 Nuvelo,Inc. Novel nucleic acids and polypeptides
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
GB2385052A (en) 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP2005253301A (ja) 2002-02-20 2005-09-22 Taisho Pharmaceut Co Ltd 骨形成蛋白結合領域を有する蛋白質及びそれをコードする遺伝子
WO2003073991A2 (en) 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
US20050287135A1 (en) 2002-05-17 2005-12-29 Wyeth Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
AU2003286757B2 (en) 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004062621A2 (en) 2003-01-13 2004-07-29 Georgia Tech Research Corporation Anti-inflammatory agents and methods of their use
PT1608399E (pt) 2003-03-14 2012-04-13 Ucb Mfg Inc Complexo de esclerostina e noguina ou cordina, e agentes que modulam a formação do referido complexo
EP1622567B1 (en) 2003-05-07 2013-07-24 Merck Sharp & Dohme Corp. Androgen receptor modulators and methods of use thereof
NO345763B1 (no) 2003-06-16 2021-07-19 Celltech R&D Inc Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering.
AU2004269920A1 (en) 2003-09-11 2005-03-17 Association Francaise Retinitis Pigmentosa (Afrp) Novel targets for the treatment of retina diseases
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20080249038A1 (en) 2003-10-07 2008-10-09 Quark Biotech, Inc. Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
CN1976726A (zh) 2004-05-14 2007-06-06 贝勒医学院 用于调节骨量的组合物和方法
EP1751185A2 (en) 2004-05-27 2007-02-14 Acceleron Pharma Inc. Tgf derepressors and uses related thereto
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20060293667A1 (en) 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2006135734A2 (en) 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
WO2007080129A1 (en) 2006-01-13 2007-07-19 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
EP4176884A1 (en) 2006-12-29 2023-05-10 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EA201070740A1 (ru) 2007-12-14 2010-12-30 Эмджен Инк. Способ лечения перелома кости антителами против склеростина
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Dkk1抗體及使用方法
CA2828000A1 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
PT3404041T (pt) 2011-04-19 2020-07-30 Amgen Inc Método para tratamento da osteoporose
NO2739311T3 (enExample) 2011-08-04 2018-07-21
US9657090B2 (en) 2011-12-28 2017-05-23 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
DK3334747T5 (da) 2015-08-13 2024-10-07 Amgen Inc Ladet dybdefiltrering af antigenbindende proteiner
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
MA45921A (fr) 2016-08-08 2019-06-19 Amgen Inc Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
JP7050335B2 (ja) 2016-12-21 2022-04-08 メレオ バイオファーマ 3 リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
US12503700B2 (en) 2017-03-14 2025-12-23 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US11498961B2 (en) 2017-07-27 2022-11-15 Jiangsu Hengrui Medicine Co., Ltd. SOST antibody pharmaceutical composition and uses thereof
JP2021519068A (ja) 2018-03-26 2021-08-10 アムジェン インコーポレイテッド 細胞培養において産生される抗体の総非フコシル化グリコフォーム
MX2020010092A (es) 2018-03-30 2020-10-28 Amgen Inc Variantes de anticuerpo c-terminales.
AU2019316575B2 (en) 2018-08-10 2025-05-22 Amgen Inc. Method of preparing an antibody pharmaceutical formulation

Similar Documents

Publication Publication Date Title
JP2020502219A5 (enExample)
JP2014114288A5 (enExample)
FI3478719T6 (fi) Anti-sklerostiini-vasta-aineiden käyttö synnynnäisen luutumisvajauden hoitamisessa
JP2017160208A5 (enExample)
JP2016535020A5 (enExample)
JP2016537340A5 (enExample)
JP2016528247A5 (enExample)
JP2015525798A5 (enExample)
JP2017500018A5 (enExample)
JP6554155B2 (ja) Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法
JP2020502218A5 (enExample)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
CN103154031A (zh) 利用il-17拮抗剂治疗牛皮癣的方法
JP2016530280A5 (enExample)
CN103189074A (zh) 使用il-17拮抗剂治疗类风湿性关节炎的方法
JP2014514346A5 (enExample)
JP2019510739A5 (enExample)
JP2016515124A5 (enExample)
JP2017160178A5 (enExample)
JP2018515493A5 (enExample)
JP2017536391A (ja) Il−6rアンタゴニストを投与することによってドライアイ疾患を治療するための方法
JP2019532970A5 (enExample)
JP2018529661A5 (enExample)
JP2018512402A5 (enExample)
JP2019519584A5 (enExample)